Sufentanil

Generic Name: Sufentanil

Brand Names: Dsuvia, Sufenta, Dzuveo

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₃₀N_₂O_₂S

CAS Number: 56030-54-7

Unique Ingredient Identifier: AFE2YW0IIZ

Background: Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes.
...

Indication: The indications for this drug are as follows:

Associated Conditions: Acute Pain, Severe Acute Pain

Associated Therapies: General Anesthesia, Induction and Maintenance of General Anesthesia, Lumbar epidural anesthesia therapy, Short opioid analgesia requirement

Clinical Trials

Analgesic Efficacy of an Opioid-free Postoperative Pain Management Strategy Versus a Conventional Opioid-based Strategy Following Video-assisted Thoracoscopic Lobectomy

Early Phase 1

Not yet recruiting

Conditions: Postoperative Pain

Interventions: Drug: Ropivacaine
Drug: Sufentanil

First Posted Date: 2024-08-26

Last Posted Date: 2024-08-26

Lead Sponsor: Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Target Recruit Count: 140

Registration Number: NCT06570538

Esketamine Anesthesia in Thoracic Surgery

Not Applicable

Not yet recruiting

Conditions: General Anesthesia
Thoracic Surgery

Interventions: Drug: Esketamine
Drug: Sufentanil

First Posted Date: 2024-03-15

Last Posted Date: 2024-05-17

Lead Sponsor: Hui Xu

Target Recruit Count: 84

Registration Number: NCT06310785

Effect of Sufentanil on the Postoperative Pain

Not Applicable

Not yet recruiting

Conditions: Postoperative Pain, Acute

Interventions: Drug: Sufentanil
Drug: Remifentanil

First Posted Date: 2024-02-15

Last Posted Date: 2024-02-15

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 48

Registration Number: NCT06260046

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of

Gynecologic Endoscopic Surgery of Female Motion Sickness Patients

Phase 4

Completed

Conditions: Motion Sickness
Postoperative Nausea and Vomiting
Ibuprofen

Interventions: Drug: Ibuprofen
Drug: sufentanil

First Posted Date: 2024-01-31

Last Posted Date: 2024-01-31

Lead Sponsor: Second Hospital of Jilin University

Target Recruit Count: 66

Registration Number: NCT06232785

Locations: 🇨🇳
Second Hospital of Jilin University, Changchun, Jilin, China

Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric

Phase 3

Not yet recruiting

Conditions: Vaso-occlusive Crisis

Interventions: Drug: Sufentanil

First Posted Date: 2023-12-26

Last Posted Date: 2023-12-26

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 182

Registration Number: NCT06181695

Effects of Sufentanil on the Intraoperative Hemodynamics

Not Applicable

Recruiting

Conditions: Intraoperative Hypotension

Interventions: Drug: Sufentanil
Drug: Remifentanil

First Posted Date: 2023-10-19

Last Posted Date: 2023-11-27

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 92

Registration Number: NCT06091904

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of

Evaluation of the Hemodynamic Effect of Dexmedetomidine in Scheduled Outpatient Surgery

Not Applicable

Recruiting

Conditions: Ambulatory Care
Anesthesia
Dexmedetomidine
Hemodynamics

Interventions: Drug: Dexmedetomidine
Drug: Sufentanil

First Posted Date: 2023-10-13

Last Posted Date: 2023-11-29

Lead Sponsor: Centre Hospitalier Universitaire de Nīmes

Target Recruit Count: 594

Registration Number: NCT06082856

Locations: 🇫🇷
CHU de Nîmes, Nîmes, France

The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE

Phase 4

Completed

Conditions: Hepatocellular Carcinoma
Transcatheter Arterial Chemoembolization
Pain
Inflammation

Interventions: Drug: Oxycodone
Drug: Sufentanil

First Posted Date: 2023-09-18

Last Posted Date: 2024-02-28

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 40

Registration Number: NCT06041425

Locations: 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China

Efficacy and Safety of Hydromorphone-ropivacaine Versus Sufentanil-ropivacaine for Epidural Labor Analgesia

Phase 2

Recruiting

Conditions: Labor Pain
Analgesia

Interventions: Drug: Sufentanil
Drug: Hydromorphone
Drug: Ropivacaine

First Posted Date: 2023-09-14

Last Posted Date: 2023-10-26

Lead Sponsor: Maternal and Child Health Hospital of Hubei Province

Target Recruit Count: 240

Registration Number: NCT06036797

Locations: 🇨🇳
Maternal and Child Health Hospital of Hubei Province, Wuhan, Hubei, China

Nalbuphine in ARDS Patients After Surgery

Phase 4

Recruiting

Conditions: Acute Respiratory Distress Syndrome

Interventions: Drug: Nalbuphine
Drug: Sufentanil

First Posted Date: 2023-09-14

Last Posted Date: 2024-03-13

Lead Sponsor: Hairong Chen

Target Recruit Count: 60

Registration Number: NCT06037330

Locations: 🇨🇳
Department of Intensive Care Medicine, Jinan, Shandong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy